Literature DB >> 24755308

Influence of cholinesterase inhibitors, donepezil and rivastigmine on the acquisition, expression, and reinstatement of morphine-induced conditioned place preference in rats.

Kinga Gawel1, Krzysztof Labuz2, Malgorzata Jenda1, Jerzy Silberring3, Jolanta H Kotlinska4.   

Abstract

The influence of systemic administration of cholinesterase inhibitors, donepezil and rivastigmine on the acquisition, expression, and reinstatement of morphine-induced conditioned place preference (CPP) was examined in rats. Additionally, this study aimed to compare the effects of donepezil, which selectively inhibits acetylcholinesterase, and rivastigmine, which inhibits both acetylcholinesterase and butyrylcholinesterase on morphine reward. Morphine-induced CPP (unbiased method) was induced by four injections of morphine (5 mg/kg, i.p.). Donepezil (0.5, 1, and 3 mg/kg, i.p.) or rivastigmine (0.03, 0.5, and 1 mg/kg, i.p.) were given 20 min before morphine during conditioning phase and 20 min before the expression or reinstatement of morphine-induced CPP. Our results indicated that both inhibitors of cholinesterase attenuated the acquisition and expression of morphine CPP. The results were more significant after rivastigmine due to a broader inhibitory spectrum of this drug. Moreover, donepezil (1 mg/kg) and rivastigmine (0.5 mg/kg) attenuated the morphine CPP reinstated by priming injection of 5mg/kg morphine. These properties of both cholinesterase inhibitors were reversed by mecamylamine (3 mg/kg, i.p.), a nicotinic acetylcholine receptor antagonist but not scopolamine (0.5 mg/kg, i.p.), a muscarinic acetylcholine receptor antagonist. All effects of cholinesterase inhibitors were observed at the doses that had no effects on locomotor activity of animals. Our results suggest beneficial role of cholinesterase inhibitors in reduction of morphine reward and morphine-induced seeking behavior. Finally, we found that the efficacy of cholinesterase inhibitors in attenuating reinstatement of morphine CPP provoked by priming injection may be due to stimulation of nicotinic acetylcholine receptors.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Conditioned place preference; Donepezil; Morphine; Rivastigmine

Mesh:

Substances:

Year:  2014        PMID: 24755308     DOI: 10.1016/j.bbr.2014.04.019

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  6 in total

1.  GluR2-3Y Inhibits the Acquisition and Reinstatement of Morphine-Induced Conditioned Place Preference in Rats.

Authors:  Xiao-Jing Lin; Jian-Jun Zhang; Long-Chuan Yu
Journal:  Neurosci Bull       Date:  2016-02-29       Impact factor: 5.203

2.  Huperzine A inhibits immediate addictive behavior but not behavioral sensitization following repeated morphine administration in rats.

Authors:  Jinling Sun; Lin Tian; Ruisi Cui; Xinwang Li
Journal:  Exp Ther Med       Date:  2017-02-02       Impact factor: 2.447

Review 3.  The Cholinergic System as a Treatment Target for Opioid Use Disorder.

Authors:  Kevin P Jensen; Elise E DeVito; Sarah Yip; Kathleen M Carroll; Mehmet Sofuoglu
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

Review 4.  A threshold model for opposing actions of acetylcholine on reward behavior: Molecular mechanisms and implications for treatment of substance abuse disorders.

Authors:  Kenneth Grasing
Journal:  Behav Brain Res       Date:  2016-06-15       Impact factor: 3.332

5.  Revealing the Molecular Mechanisms of Alzheimer's Disease Based on Network Analysis.

Authors:  Abdulahad Bayraktar; Simon Lam; Ozlem Altay; Xiangyu Li; Meng Yuan; Cheng Zhang; Muhammad Arif; Hasan Turkez; Mathias Uhlén; Saeed Shoaie; Adil Mardinoglu
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

6.  Cholinesterase inhibitors, donepezil and rivastigmine, attenuate spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats.

Authors:  Kinga Gawel; Krzysztof Labuz; Ewa Gibula-Bruzda; Malgorzata Jenda; Marta Marszalek-Grabska; Joanna Filarowska; Jerzy Silberring; Jolanta H Kotlinska
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-07-04       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.